Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors

1 Nov 2017

Abstract excerpt

-phase cells in the absence of immediate DNA replication stress. Accordingly, AZD6738 exhibited nanomolar potency against most neuroblastoma, medulloblastoma, Ewing sarcoma, and rhabdoid tumor cells tested while sparing nontransformed human and mouse embryonic fibroblasts in vitro. Finally, treatment with AZD6738 induced apoptosis and regression of human neuroblastoma and medulloblastoma tumors engrafted in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29093183
DOI: 10.1126/scitranslmed.aam9078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumorsPMID 29093183Read ↗

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumorsSemantic proximity Read ↗

Targeting the DNA damage response in pediatric malignancies.Semantic proximity Read ↗

Transcriptomics-guided high-throughput drug screening identifies potent therapies for P53 pathway altered DIPG/DMG.Semantic proximity Read ↗

DNA Damage Response Deficiency Enhances Neuroblastoma Progression and Sensitivity to Combination PARP and ATR InhibitionSemantic proximity Read ↗

DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibitionSemantic proximity Read ↗

Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in NeuroblastomaSemantic proximity Read ↗

Clinical Response to a PARP Inhibitor and Chemotherapy in a Child with BARD1-Mutated Refractory Neuroblastoma: A Case ReportSemantic proximity Read ↗

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.Semantic proximity Read ↗

Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood EpendymomaSemantic proximity Read ↗

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationSemantic proximity Read ↗

Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcomaSemantic proximity Read ↗

ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade gliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.